Snyder, Raymond; Boyle, Frances; Chan, Arlene; Craft, Paul; De Boer, Richard; Mainwaring, Paul; McCarthy, Nicole; Wilcken, Nick
Primary and acquired resistance to trastuzumab pose a therapeutic challenge when treating patients with HER2 (erbB-2)-positive locally advanced or metastatic breast cancer (MBC). The recent introduction of lapatinib (Tykerb/Tyverb, GlaxoSmithKline, Brentford, UK) provides a new management option for such patients. A prospective, randomized phase III clinical trial has confirmed that lapatinib in combination with capecitabine extends time to progressive disease in HER2-positive MBC, compared...[Show more]
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.